Strategic partnership Valeritas has a history of partnerships and acquisitions in the diabetes space, including past collaborations and asset sales. This indicates openness to strategic alliances and potential co-development or distribution partnerships to expand V-Go adoption in new territories or clinical settings.

US market focus The V-Go device is cleared and commercially available in the United States, signaling strong domestic demand potential. Sales opportunities could focus on expanding payer coverage, hospital systems, and primary care networks within the U.S., leveraging existing regulatory clearance.

Small company agility With a lean employee base, Valeritas is likely to respond quickly to pilot programs and targeted deployments. This presents an opportunity for scalable, low-friction pilots with clinics, diabetes centers, and home health providers to demonstrate value and drive rapid adoption.

Cost and efficiency focus Real-world analyses show V-Go can lower A1C while reducing insulin use. This cost-efficiency narrative can be leveraged in discussions with payers, risk-bearing providers, and formularies to secure favorable coverage and volume-based contracts.

Expansion potential Past activities include international presence and partnerships, suggesting room to explore international distribution, collaborations with global formulary groups, and integration with diabetes management programs to broaden market reach.